Provided By GlobeNewswire
Last update: Jun 10, 2025
ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT).
Read more at globenewswire.comNASDAQ:PHVS (7/25/2025, 8:16:51 PM)
20.62
+0.57 (+2.84%)
Find more stocks in the Stock Screener